Skip to main content
SpringerLink
Log in

Does CRISPR-Cas open new possibilities for patents or present a moral maze?

  • Patents
  • Published:

From Nature Biotechnology

View current issue Submit your manuscript

CRISPR-Cas systems, which enable the production of new artificial genes, synthetic proteins and new transgenic organisms, will challenge patent practices worldwide.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Jinek, M. et al. Science 337, 816–821 (2012).

    Article  CAS  Google Scholar 

  2. Jiang, W. et al. Nat. Biotechnol. 31, 233–239 (2013).

    Article  CAS  Google Scholar 

  3. Cho, S.W. et al. Nat. Biotechnol. 31, 230–232 (2013).

    Article  CAS  Google Scholar 

  4. Hwang, W.Y. et al. Nat. Biotechnol. 31, 227–229 (2013).

    Article  CAS  Google Scholar 

  5. Urnov, F.D. et al. Nat. Rev. Genet. 11, 636–646 (2010).

    Article  CAS  Google Scholar 

  6. Association for Molecular Pathology et al. v. Myriad Genetics, Inc. et al. http://www.supremecourt.gov/opinions/12pdf/12-398_1b7d.pdf (13 June 2013).

  7. Directive 98/44/EC of the European Parliament and of the Council of 6 July 1998 on the legal protection of biotechnological inventions, Official Journal L213, 0013–0021 (30 July 1998). http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=CELEX:31998L0044:EN:HTML

  8. Diamond v. Chakrabarty, 447 US 303 (1980).

  9. Patent no. 3, granted in Finland in 1843.

  10. Plant Genetics Systems NV and Biogen, Inc. European Patent No. 0 242 236 (10 October 1990).

  11. T0356/93 Plant cells/Plant Genetic Systems http://www.epo.org/law-practice/case-law-appeals/recent/t930356ep1.html

  12. T 0019/90 Onco-Mouse/Harvard http://www.epo.org/law-practice/case-law-appeals/recent/t900019ex1.html.

  13. Recital 16 of the Directive 98/44/EC of the European Parliament and of the Council of 6 July 1998 on the legal protection of biotechnological inventions, Official Journal L213, 0013–0021 (30 July 1998). http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=CELEX:31998L0044:EN:HTML

Download references

Author information

Authors and Affiliations

  1. Philip Webber is at Dehns Patent and Trade Mark Attorneys, Oxford, UK.,

    Philip Webber

Authors
  1. Philip Webber
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Philip Webber.

Ethics declarations

Competing interests

The author declares no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Webber, P. Does CRISPR-Cas open new possibilities for patents or present a moral maze?. Nat Biotechnol 32, 331–333 (2014). https://doi.org/10.1038/nbt.2843

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt.2843

  • Springer Nature America, Inc.

This article is cited by

Search

Navigation